MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction.
OBJECTIVE
To investigate the effects of Xiezhuo Chubi Decoction (XZCBD) on the microRNA expression patterns of kidney in mice with hyperuricemia.


METHODS
Sixty Kunming male mice were randomly divided into the high-, medium-, and low-dose XZCBD groups, benzbromarone group, model group, and control group. Except the control group, all mice were established with yeast method combined with uricase inhibition method to build hyperuricemia model, and the corresponding drugs (37.5 g/kg, 18.75 g/kg, 9.375 g/kg, and 0.02 g/kg per day) were administrated on the 7th day. On the 22nd day, the blood uric acid concentration was detected, and microRNA with obvious changes in kidney was screened with qRT-PCR.


RESULTS
The uric acid in the model group was higher than that in the control group, and the levels of the uric acid were reduced after being treated with XZCBD; the differences among groups were significant (P<0.05). Compared with the control group, 32 kinds of microRNA expression changes were detected on the 15th day after being treated with high-dose XZCBD by microRNA expression profile screening. Among them, miR-34a could inhibit the expression of human urate anion exthanger 1, and miR-146a might have inhibited the inflammatory reaction.


CONCLUSIONS
XZCBD could significantly reduce the serum uric acid level; its effect on hyperuricemia might be through affecting microRNA expressions.
Department of Traditional Chinese Medicine, General Hospital of Guangzhou Military Command of PLA, Guangzhou 510010, China. sunwf3@sina.com
Wei-Feng
WF
Sun
Xian-Xian
XX
Zhang
Fen-Yong
FY
Sun
Wei
W
Xu
Jing
J
Liang
Shu-Mei
SM
Feng
Tian
T
Wang
D000818:Animals; D001483:Base Sequence; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000494:pharmacology / Q000627:therapeutic use*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D033461:Hyperuricemia / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D035683:MicroRNAs / Q000235:genetics*; D008969:Molecular Sequence Data; D027361:Organic Anion Transporters / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014527:Uric Acid / Q000097:blood
D004365:Drugs, Chinese Herbal; D035683:MicroRNAs; D027361:Organic Anion Transporters; C109687:Slc22a12 protein, mouse; C557892:xiezhuo chubi; D014527:Uric Acid
Nature. 2008 Dec 18;456(7224):980-4
19043405
J Virol. 2008 Apr;82(8):3997-4006
18256146
Am J Hypertens. 2008 Oct;21(10):1157-62
18670416
Cell. 2005 Jan 14;120(1):15-20
15652477
J Cell Physiol. 2007 Feb;210(2):279-89
17096367
Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4034-9
16495412
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):646-51
18174328
Pediatr Nephrol. 2005 Jul;20(7):886-90
15912381
Mol Biol Cell. 2008 Aug;19(8):3272-82
18508928